Journal article icon

Journal article

Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.

Abstract:

Cediranib is a highly potent and selective vascular endothelial growth factor (VEGF) signaling inhibitor with activity against all three VEGF receptors (VEGFRs) that inhibits angiogenesis and growth of human tumor xenografts in vivo. The present study evaluated the antitumor and antiangiogenic activity of cediranib in the clinically relevant, murine renal cell carcinoma (RENCA) model and its biological response using VEGF and sVEGFR-2 as biomarkers. Mice were treated with cediranib (5 mg/kg/d...

Expand abstract
Publication status:
Published

Actions


Authors


Expand authors...
Journal:
Anticancer research
Volume:
29
Issue:
12
Pages:
5065-5076
Publication date:
2009-12-01
EISSN:
1791-7530
ISSN:
0250-7005
Source identifiers:
315723

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP